Immunomodulatory Activity of Atractylodes lancea in Healthy Volunteers and Model-Based Dose Selection for Cholangiocarcinoma Therapy
Teerachat Saeheng
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand and Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand.
Kesara Na-Bangchang *
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand and Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathum Thani, Thailand and Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Pathum Thani, Thailand.
*Author to whom correspondence should be addressed.
Abstract
This study brings together three distinct sources of evidence, which are kept separate throughout. (i) Previously reported healthy-volunteer data: in an earlier placebo-controlled phase I study in healthy Thai volunteers, Atractylodes lancea (Thunb.) DC. (AL) 1,000 mg once daily for 21 days significantly reduced the circulating levels of the cytokine panel measured (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-alpha and IFN-gamma) and altered several peripheral immune cell populations; that study did not define a maximum tolerated dose (MTD) or a regimen for phase IIA testing. (ii) New model-derived predictions generated in the present work: a whole-body physiologically based pharmacokinetic (PBPK) model of atractylodin, the principal constituent, was constructed in SimBiology, validated against the observed clinical concentration-time data (overall absolute average fold error 1.17) subjected to sensitivity analysis and subsequently used to simulate once-, twice- and four-times-daily regimens up to 10,000 mg/day. Predicted haematological toxicity (Emax model, with peripheral blood mononuclear cell inhibition as a surrogate) and predicted hepatotoxicity (unbound liver Cmax ratio, assuming a linear dose-enzyme relationship) were simulated in 100 virtual subjects. On these model-derived criteria, 500 mg four times daily was identified as the proposed first-in-human regimen, 2,500 mg four times daily as the model-predicted upper tolerated regimen (a prediction, not an observed MTD), and 1,500 or 2,000 mg once daily as the regimens proposed for phase IIA evaluation. (iii) Preliminary clinical observations: in the subsequent phase IIA trial, 2,000 mg once daily was associated with better disease control and survival than 1,000 mg once daily; these are preliminary, descriptive observations reported in full elsewhere, and no clinical methodology or statistical analysis is presented in this study. PBPK modelling combined with a toxicological approach can therefore assist dosage-regimen selection for clinical studies, including studies of herbal medicines, provided the model-derived values are confirmed clinically.
Keywords: Atractylodes lancea, atractylodin, immunomodulation, physiologically based pharmacokinetic (PBPK) model, dose finding, cholangiocarcinoma